BUSINESS OVERVIEW
BenevolentAI (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery.
BenevolentAI is a leading developer of advanced artificial intelligence technologies that unlock the value of multimodal data, surface novel insights, and accelerate biomedical discovery
Through the combined capabilities of its AI platform, its scientific expertise, and wet-lab facilities, the Company is developing an inhouse drug pipeline of high-value assets. The Company is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Reports and presentations
| Date and title | 20 Mar 2024 Annual Report 2023 |
|---|---|
| Document | View |
| View ESEF XHTML | |
| Download ESEF ZIP |
Announcements
EMAIL ALERTS
Get alerts for our announcements
Investor events, conference attendance and annual reporting.